Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

CureVac Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

CureVac wird ein jährliches Gewinn- und Umsatzwachstum von 56.2% bzw. 25.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 55.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -97.1% betragen.

Wichtige Informationen

56.2%

Wachstumsrate der Gewinne

55.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.6%
Wachstumsrate der Einnahmen	25.8%
Zukünftige Eigenkapitalrendite	-97.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	30 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29

Recent updates

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

Jun 01

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

Mar 20

CureVac: No Momentum In Sight

Mar 08

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Aug 26

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 14

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

May 01

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Apr 29

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Jan 08

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued

Jun 13

CureVac tumbles on potential delay for European decision on its COVID-19 shot

Jun 08

CureVac: The Moment Of Truth Arrives

Jun 01

CureVac BV reports Q1 results

May 26

CureVac Could Soon Join The Fight Against COVID-19

May 10

CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability

May 02

How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?

Mar 03

CureVac expands Phase 1 Trial for CV8102 in advanced Melanoma

Feb 04

Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)

Jan 27

CureVac's COVID-19 vaccine shows promise in preclinical study of non-human primates

Jan 11

CureVac, Bayer agree to COVID-19 vaccine alliance - report

Jan 07

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:CVAC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	123	-65	-73	N/A	6
12/31/2025	86	-130	-179	N/A	8
12/31/2024	56	-211	-342	N/A	8
3/31/2024	59	-273	-312	-265	N/A
12/31/2023	54	-260	-323	-268	N/A
9/30/2023	43	-302	-335	-273	N/A
6/30/2023	38	-301	-325	-249	N/A
3/31/2023	50	-291	-338	-249	N/A
12/31/2022	67	-249	-379	-286	N/A
9/30/2022	97	-122	-527	-420	N/A
6/30/2022	115	-219	-758	-659	N/A
3/31/2022	117	-313	-782	-673	N/A
12/31/2021	103	-412	-861	-733	N/A
9/30/2021	68	-468	-228	-109	N/A
6/30/2021	44	-361	N/A	N/A	N/A
3/31/2021	56	-219	250	329	N/A
12/31/2020	49	-129	475	522	N/A
9/30/2020	50	-107	36	62	N/A
3/31/2020	17	-102	-82	-67	N/A
12/31/2019	17	-100	-99	-87	N/A
12/31/2018	13	-71	-89	-74	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CVAC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CVAC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CVAC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CVACDie Einnahmen des Unternehmens (25.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: CVACDie Einnahmen des Unternehmens (25.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CVAC wird voraussichtlich in 3 Jahren unrentabel sein.

CureVac Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 17%

Consensus revenue estimates increase by 13%, EPS downgraded

Consensus revenue estimates decrease by 29%, EPS upgraded

Consensus revenue estimates increase by 57%

Consensus revenue estimates decrease by 42%, EPS upgraded

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Recent updates

Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking

CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

New major risk - Financial position

CureVac N.V. to Report Q1, 2024 Results on May 23, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024

CureVac N.V. to Report Q4, 2023 Results on Apr 24, 2024

CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully

CureVac: No Momentum In Sight

CureVac N.V. Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

CureVac N.V. Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

CureVac N.V. to Report Q3, 2023 Results on Nov 14, 2023

Consensus EPS estimates fall by 17%

Consensus revenue estimates increase by 13%, EPS downgraded

What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 29%, EPS upgraded

CureVac N.V. to Report Q2, 2023 Results on Aug 17, 2023

CureVac N.V. Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 Mrna Vaccine Candidates Developed in Collaboration with GSK

CureVac N.V. Announces Executive Changes

CureVac N.V. Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma

Consensus revenue estimates increase by 57%

CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price

Consensus revenue estimates decrease by 42%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CureVac N.V., Annual General Meeting, Jun 19, 2023

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates

Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results

Full year 2022 earnings: EPS and revenues miss analyst expectations

CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer

CureVac N.V. Announces Positive Data in Older Adults from Covid-19 and Flu mRNA Vaccine Development Programs

Now 31% undervalued

CureVac N.V. Announces CEO Changes

An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued

Third quarter 2022 earnings released: €0.25 loss per share (vs €0.77 loss in 3Q 2021)

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

CureVac N.V. to Report Q3, 2022 Results on Nov 16, 2022

No longer forecast to breakeven

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

CureVac Announces Executive Changes

CureVac BV reports Q2 results

Consensus estimates of losses per share improve by 10%

CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine

CureVac N.V. Announces Board Changes

CureVac N.V. (NasdaqGM:CVAC) acquired Frame Therapeutics B.V. for €32 million.

CureVac N.V. Announces Changes of CDO

CureVac N.V., Annual General Meeting, Jun 22, 2022

Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?

Insider notifies of intention to sell stock

Consensus forecasts updated

Consensus forecasts updated

Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 36%

Forecast breakeven date pushed back to 2024

CureVac N.V. to Report Q4, 2021 Results on Apr 28, 2022

CureVac N.V Announces Preclinical Data Demonstrating Immune Responses and Protective Efficacy of Bivalent Second-Generation COVID-19 Vaccine Candidate Jointly Developed with GSK

CureVac N.V. and GSK Start Clinical Development of Second-Generation Covid-19 Vaccine Candidate, CV2CoV

CureVac N.V. Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2023

A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)

CureVac Streamlines European Network for mRNA Product Manufacturing

CureVac: Wait For Concrete News Before Investing

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Forecast breakeven moved forward to 2021